IGHE and chronic idiopathic urticaria: <h4>Background</h4>Omalizumab, an anti-IgE antibody, is recommended as a second-line therapy for chronic spontaneous urticaria in patients aged ≥12 years; however, real-world evidence for its use in younger Chinese children remains limited.